BCR-ABL Point Mutations and TKI Treatment in CML Patients


Most newly diagnosed CML patients in the Chronic Phase (CP), when treated with imatinib, achieve durable responses. However, a small percentage of these patients as well as most advanced-phase patients relapse on imatinib therapy. Among several resistant mechanisms, “point mutation within the BCR-ABL kinase domain” that interferes with imatinib binding is… (More)


7 Figures and Tables